Related Experiment Video
Updated: Jun 10, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
[Study of sequence-dependent in vitro effects of zoledronic acid and paclitaxel upon DU145 prostate cancer cells]
Zhong-yi Zhang1, Li-qun Zhou, Yi Ding
1Institute of Urology, Peking University First Hospital, Beijing 100034, China.
Objective:
To investigate the anti-proliferation and pro-apoptotic effects of different sequence schemes of zoledronic acid plus paclitaxel upon the hormone-refractory prostate cancer cell lines DU145 in vitro so as to provide the potentially optimal sequence scheme of these two drugs.
Methods:
MTT assay and Annexin V-FITC/PI double-staining flow cytometry were employed to observe the effects of zoledronic acid plus paclitaxel upon anti-proliferation and apoptosis induction respectively.
Results:
Inhibition of cellular growth by (44.17+/-5.81)% was observed under the treatment of paclitaxel and then zoledronic acid. Such a regimen was superior to the treatment of zoledronic acid and then paclitaxel or zoledronic acid (32.81+/-5.13)% plus paclitaxel (36.43+/-5.75)%. In comparisons with other groups, the treatment of paclitaxel and then zoledronic acid induced the maximal apoptosis (14.96%) and necrosis (14.37%) as shown by Annexin V-FITC/PI double-staining flow cytometry.
Conclusion:
For the maximal anti-proliferation and apoptosis, DU145 cells should be treated with paclitaxel then zoledronic acid. Such a regimen provides the optimal scheme for the sequence-dependent treatment.
